Basilea buys rights to fosmanogepix, a broad-spectrum antifungal

Swiss drugmaker Basilea Pharmaceutica (SIX: BSLN) has entered into an asset purchase agreement with Amplyx Pharmaceuticals, which was bought in 2021 by US pharma giant Pfizer (NYSE: PFE), to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate.

In addition, Basilea has acquired the rights to a pre-clinical antifungal compound, with the two candidates adding to Basilea’s acquisition of rights to Gravitas Therapeutics’ GR-2397, also a clinical-stage antifungal compound

Fosmanogepix is a potential first-in-class antifungal treatment candidate with a novel mechanism of action. It is available in intravenous and oral formulations and has been evaluated for efficacy and safety in a Phase I/I program, including three open-label Phase II studies for the treatment of Candidemia, including Candida auris, and invasive mold infections.